Expression quantitative trait loci (eQTLs) identified using tumor gene expression data could affect gene expression 21 in cancer cells, tumor-associated normal cells, or both. Here, we demonstrate a method to identify eQTLs affecting 22 expression in cancer cells by modeling the statistical interaction between genotype and tumor purity. Only one-third 23 of breast cancer risk variants, identified as eQTLs from a conventional analysis, could be confidently attributed to 24 cancer cells. The remaining variants could affect cells of the tumor microenvironment, such as immune cells and 25 fibroblasts. Deconvolution of tumor eQTLs will help determine how inherited polymorphisms influence cancer 26 risk, development, and treatment response.
Background 28
Expression quantitative trait loci (eQTLs) have been mapped in many tumor types, including high-profile studies in 29 glioma [1] , colon[2], breast [3] and prostate cancer [4] . These studies measured genome-wide gene expression in
Results

79
A conventional tumor eQTL mapping strategy will recover eQTLs from both cancer cells and tumor-80 associated normal cells in simulated data 81 To establish whether eQTLs in tumor-associated normal cells may indeed influence eQTL profiles recovered from 82 bulk tumor expression data, we first created a simulated dataset where underlying cancer/normal eQTL profiles 83 were known a priori. Simulations consisted of expression levels of 600 genes in pure "cancer" samples and in pure 84 "normal" tissue samples. These were then combined to simulate a "bulk tumor" expression dataset, consisting of 85 1,000 samples. Six classes of eQTLs were created, each represented by 100 genes; these were (1) genes with eQTLs 86 in cancer and normal, but with different effects in the two cell types (2) genes with eQTLs in cancer only (3) genes 87 with eQTLs in normal only (4) genes with no eQTL in either cell type (5) genes with the same eQTL in both cell 88 types and (6) genes with similar eQTLs in both cell types. Because the purpose of these simulations was to study the 89 performance of this model in real cancer data, the parameters, such as sample size, expression levels, effect sizes 90 and proportions of cancer/normal cells, were chosen to resemble the TCGA breast cancer cohort (see Methods).
92
We applied the current standard eQTL mapping strategy to these simulated data, where the expression levels from 93 bulk tumors were treated as representative of cancer itself (henceforth referred to as the "conventional model"; see 94 Methods). Importantly, the assumption here is that the goal is to identify eQTLs influencing gene expression in 95 cancer cells, therefore true simulated cancer eQTLs were treated as the ground-truth for all statistical measures of 96 performance reported in this and the next section. By comparing the results obtained from the model to the true 97 known cancer eQTLs created as part of the simulation, this approach achieved reasonable sensitivity and specificity 98 (79.5% and 80.3% respectively). However, there was a clear influence of the simulated eQTLs in the normal cells on 99 the recovered effects from bulk tumor expression (Pearson's correlation (r) = 0.9, P = 1.3 × 10 -38 between simulated 00 effect size of eQTLs with an effect in normal but not cancer cells and their estimated effect size from the 01 conventional model; Fig. 1(a) ). Furthermore, while we expected a false discovery rate (FDR; estimated using the 02 Benjamini and Hochberg approach) of 5%, the true FDR was 11.1%, when the known simulated set of cancer 03 eQTLs was treated as the ground-truth. Most (37 of 40) of these false discoveries were falsely attributed 04 associations resulting from eQTLs in normal cells ( Supplementary Table 1 ).
06
Cancer eQTLs can be accurately identified from bulk tumor expression data by modeling the interaction 07 of tumor purity and genotype in simulated data 08 To recover cancer eQTLs from bulk tumor expression data, we have built upon (see Methods) a previous study to 09 identify eQTLs with different effects in human neutrophils and lymphocytes using whole blood expression data [17] . 10 Like conventional eQTL mapping, our new approach involves fitting a linear regression model of gene expression 11 level against genotype: However, in addition to genotype, the estimated proportion of tumor-associated normal cells 12 (tumor purity) is included as a covariate, as well as the interaction between the estimated tumor purity and genotype 13 (henceforth referred to as the "interaction model"; see Methods). Critically, the estimate of the main effect 14 associated with this interaction term allows the eQTL to be assigned to cancer, not the interaction term itself (see The interaction model recovered simulated cancer eQTLs with a sensitivity and specificity of 58.3% and 96.1% Supplementary Figure 1 ) was expected given the 22 extrapolation to a cell type-specific state and the simulations taking account of the potential for shared eQTLs 23 between cancer and normal cell types. However, the true FDR dropped to 3.3%, below the expected rate of 5%.
24
Only two "normal only" (group 3; see Methods) eQTLs were misattributed to cancer and the influence of normal 25 cells observed for the conventional model was eliminated ( Fig. 1(b) ; Supplementary Table 2 ). To further illustrate 26 the utility of the model, a normal-driven eQTL analyzed with a conventional model is shown in Fig. 1(c) , along with 27 the capacity of the interaction model to extrapolate the correct effect size in cancer cells, deducing that this signal 28 was driven by samples with large quantities of tumor-associated normal cells ( Fig. 1(d) ).
30
In cancer eQTL mapping, the assumption has been implicit that the eQTLs identified from tumor samples affect 31 gene expression in cancer cells. However, the pervasive genomic aberrations and dysregulation of key master 32 regulators that occurs in cancer cells[18] could obscure or eliminate associations between germline polymorphisms 33 and gene expression, either by increasing transcriptional noise or by disrupting the regulatory landscape. Thus, the 34 inherited genetic influence on gene expression could be far greater in normal cells than in cells that have undergone 35 neoplastic transformation. To assess the plausibility that eQTLs previously discovered from tumor expression data 36 could be largely driven by normal cells, we included an additional 500 genes with "normal only" eQTLs in our 37 simulated dataset. Again, assuming the objective is to identify eQTLs that affect gene expression in cancer cells, a 38 conventional model applied to bulk tumor expression data performs very poorly. Using an FDR threshold of 5% 39 we in fact observed a rate of false discovery rising to 46% of significant associations ( Supplementary Table 3 ). Of 40 the 270 false discoveries, 267 were misattributed eQTLs affecting gene expression in normal cells only. However, 41 when the interaction model was used, the rate of false discovery was again accurately controlled (3% false 42 discoveries at an imposed FDR threshold of 5%) and only 5 eQTLs in normal cells (<1%) were misattributed to 43 cancer. Furthermore, the interaction model could accurately identify true cancer eQTLs even when tumor purity 44 was measured with noise similar to levels expected in real data[19] ( Fig. 1 (e); see Methods for details). Notably, just 45 including the proportion of cancer cells as a covariate in a conventional model had no impact on the performance, 46 with the observed FDR remaining at 45.9% (at the imposed 5% threshold; Supplementary Table 3 ). Thus, tumor 47 purity cannot simply be "accounted for" by including it as a model covariate or including surrogate variables that 48 approximate tumor purity such as principal components or PEER factors-modeling the interaction of tumor 49 purity and genotype is absolutely critical to correctly assign eQTLs to cancer cells. Ignoring this can potentially 50 falsely attribute enormous numbers of eQTLs from tumor-associated normal cells. Notably, simply restricting to 51 tumors with higher cancer cell content is also likely not an optimal solution this problem; doing so caused a large While no simulated dataset can capture the full complexity of in vivo biology, these analyses suggest that (i) it is 55 plausible that many, if not most eQTLs identified from tumor expression data using conventional approaches 56 actually affect gene expression in normal cells, not in cancer cells and (ii) using the parameters of the TCGA breast 57 cancer data, modeling the interaction of tumor purity and genotype performs well at correctly attributing true cancer 58 eQTLs. Below, we perform a case-study using an integrative analysis of real data from TCGA breast cancer, breast 59 cancer GWAS results, and samples from the Genotype-tissue Expression (GTEx) project.
61
Case-study: mapping cis-eQTLs in breast cancer
62
To test the utility of the interaction model on real data, we conducted cis-eQTL mapping in TCGA breast cancer 63 samples, where both germline genotype and bulk tumor RNA-Seq data were available (n = 894). We also applied a 64 conventional model to bulk tumor expression data (see Methods). We focused on breast cancer as it has the largest 65 available sample size, and is reasonably representative of tumor types with high normal cell contamination ( Fig.   66 2(a)). We estimated tumor purity using a consensus approach that combined the estimates from copy number We evaluated 3,602,220 associations between tag SNPs and the expression levels of genes within 500 kilobases of 74 each tag SNP. The data were filtered and preprocessed based on the recent guidelines of GTEx, including steps to 75 control for population structure, unmeasured confounders, and expression heterogeneity (see Methods). We 76 identified 57,189 significant cis-eQTL associations (FDR < 0.05; Fig. 3(a) ) using the conventional model. However, 77 using the interaction model, just 8,833 eQTLs could be confidently attributed to cancer cells (FDR < 0.05; Fig.   78 3(a)). Of the 8,833 associations attributed to cancer cells, 7,542 were also identified by the conventional model and . When we randomly permuted the tumor purity estimates, the number of eQTLs that could be 82 attributed to cancer cells was just 239 ( Fig. 3(a) ). We show a specific example in Figs. 3(b-e) to illustrate the process 83 of attributing eQTLs to the affected cell type. In this example, the association between SNP rs6458012 and the 84 expression of MDGA1 in breast tumors (P = 1.5 × 10 -29 ; Fig. 3 The interaction model attributes fewer immune and fibroblast-specific eQTLs to breast cancer cells in the 91 TCGA cohort 92 As outlined above, when the interaction model was used, we found that the majority (49,647; 86.8%) of the eQTLs 93 identified from bulk tumor expression data could not be attributed to cancer cells. Indeed, 18,595 of these 94 potentially falsely-attributed eQTLs were also eQTLs, with concordant directionality in one or more of normal 95 breast (8,536 eQTLs), LCL (4,531 eQTLs) or fibroblast (15,810 eQTLs) tissues in GTEx. However, cancer eQTL 96 profiles have never been studied in the absence of normal cells and germline genotypes are not typically collected 97 from cell line donors; hence, there is no established gold standard to compare the sensitivity/specificity of the 98 conventional and interaction models in real data. However, we can assess whether the interaction model eliminates 99 associations for likely immune and stromal cell-specific eQTLs. To do this, we used GTEx data to define a set of 00 eQTLs that were likely to be misattributed; i.e. they were more likely to have arisen in immune and stromal cells, 01 rather than from breast cancer cells. We defined this set as cis-eQTLs identified in lymphoblastoid cell lines (LCLs) 02 or transformed fibroblasts in GTEx (FDR < 0.05), which were not even nominally significant (P > 0.05) in GTEx 03 breast tissue. We reasoned that LCLs and fibroblasts provide a good proxy for tumor-associated immune and 04 stromal cells, while the regulatory landscape of breast cancer cells is likely to maintain a similarity to breast, the 05 tissue from which they developed. These criteria yielded a set of 47,196 eQTLs shared between GTEx and TCGA 06 that had a higher likelihood of being misattributed if identified as cancer eQTLs. Of the 57,189 significant 07 associations from the conventional model, 5,440 were among this set defined as likely arising in associated-normal 08 cells. For 8,833 associations from the interaction model, this number was reduced to 572. This is a significant 09 reduction in the proportion of these likely misattributed eQTLs ( Fig. 4 (a & b), P = 8.1 × 10 -22 from Fisher's exact 10 test, odds ratio 1.51). Thus, consistent with our simulations, there is convincing evidence in real data that the use of 11 the interaction model reduces the misattribution of eQTLs from tumor-associated normal cells. Furthermore, we 12 also mapped breast cancer eQTLs using only 10% of the TCGA breast cancer samples that had the highest 13 estimated cancer cell content (all > 88.6% purity; median = 91.2%, n = 89). As expected, the eQTL effects 14 estimated from this high purity subset were (globally) much more similar to those estimated by the interaction 20 We also expect that genes whose regulation is disrupted following tumorigenesis would be more likely to be 21 involved in cancer hallmark processes [20, 21] . Thus, for all cis-eQTLs represented in GTEx breast tissue and TCGA 22 breast cancer, we compared the magnitude of the effect of each eQTL between the two datasets (see Methods). For 23 3,885 of 3,270,829 eQTLs, there was evidence (FDR < 0.05; Supplementary Figure 5 ; Supplementary Table 6 ) of a 24 difference between breast cancer and normal breast tissue. Of these, 3,068 had a larger effect (comparing absolute 25 values) in normal breast tissue and 797 in cancer. We compiled a list of eQTL-associated genes for which there was 26 evidence of a difference in this germline mediated regulation of gene expression between cancer and normal cells.
27
Then, to determine whether these changes were biologically meaningful we assessed these genes for enrichment of 28 Gene Ontology (GO) biological process (see Methods). Indeed, the most strongly enriched processes included this dysregulation may be attributable to increased expression heterogeneity or different expression levels among 32 these genes in cancer and understanding the mechanisms by which normal regulation of these genes is disrupted 33 will represent a starting point for future mechanistic studies.
35
Validation of TCGA breast cancer findings in the METABRIC dataset 36 Next, we sought to replicate our results using an additional 997 breast tumor expression profiles and genotypes 37 generated by the METABRIC consortium [22] . Although this is the most suitable validation cohort available, there 38 are some limitations to this dataset; for example, the genotypes were generated from (less reliable) tumor tissue (see 39 Methods), and expression was estimated using a microarray platform, which is likely less sensitive than the RNA-seq 40 platform used by TCGA. Despite this, the results were similar to TCGA. Using a conventional model 47,354 41 eQTLs were identified (FDR < 0.05) in METABRIC and this number dropped to 9,235 when the interaction model 42 was applied, with an overlap of 8,142. Thus, similarly to the TCGA cohort, most tumor eQTLs identified in 43 METABRIC could not be confidently attributed to cancer cells. Despite the differences between these datasets, the 44 overlap of eQTLs identified in TCGA and METABRIC was much higher than expected by chance for both the 45 conventional and interaction models: 39.4% of tumor eQTLs identified (FDR < 0.05) by the conventional model in 46 TCGA were also significant (FDR < 0.05) when the conventional model was applied to METABRIC (57.4% 47 reached P < 0.05). 31.5% of cancer eQTLs identified (FDR < 0.05) by the interaction model in TCGA were also 48 significant (FDR < 0.05) when the interaction model was applied to METABRIC (52.4% reached P < 0.05). A 49 slight drop in this replication rate for the interaction model was expected given the additional challenge of assigning 50 eQTLs to a specific cell type, rather than just identifying bulk tissue eQTLs. to the TCGA breast tumor expression data (arising from 16 of the 81 risk SNPs that could be mapped to one-or-60 more genes; see Methods). However, 9 of these eQTLs were not even nominally significant (P > 0.05) when 61 extrapolated to cancer cells using the interaction model, suggesting these are strong candidates for eQTLs arising 62 from normal cells. Indeed, all of these 9 associations were significant in at least one of fibroblast, breast or LCLs in 63 GTEx, in all cases with the same directionality as the eQTL effect estimated from bulk tumor expression using the 64 conventional model ( Fig. 5(a & b) ; Supplementary Table 8 ). We have demonstrated an improved eQTL mapping strategy for cancer, which uses tumor purity estimates and bulk 91 tumor gene expression data to identify eQTLs that can be confidently attributed to cancer cells. In breast cancer, 92 the result is that most bulk tumor eQTLs cannot be confidently attributed to cancer cells, once the possibility of 93 these eQTLs arising from tumor-associated normal cells is appropriately modeled.
95
We demonstrated the implications for the interpretation of genetic variants associated with cancer risk. The 96 mechanism-of-action of most cancer GWAS variants remains unknown. However, if these variants affect gene 97 expression in tumor-associated normal cells, but not cancer or baseline normal cells, their disease relevance could lie 98 in modulating how the host-and in particular the cells of the tumor microenvironment-responds to the disease 99 rather than reflecting functions intrinsic to cancer (or pre-cancer) cells themselves. Furthermore, we also showed 00 that one breast cancer risk variant, rs204247, is an eQTL for RANBP9 in breast cancer cells, but not tumor-01 associated normal cells. If rs204247 affects RANBP9 expression only in breast cancer cells, and this is indeed the 02 mechanism by which this SNP pre-disposes individuals to cancer, then some earlier aberration, for example, the 03 activation of a transcription factor, must be a pre-requisite for rs204247's pathogenic effect. Such an aberration 04 might occur in pre-cancer cells, with individuals carrying the risk allele of rs204247 then manifesting the oncogenic 05 effects of increased RANBP9 expression. Interestingly, RANBP9 has been shown to interact with oncogene c-06 MET, a key regulator in development and cancer stem cells. This interaction has been shown to stimulate RAS 07 signaling, which is crucial to cancer-relevant processes such as cell differentiation, apoptosis, and motility[29], thus 08 offering a possible oncogenic mechanism of this GWAS risk allele. Notably, if this hypothesis is correct, rs204247 is 09 likely affecting druggable pathways. However, this association would not have been apparent by only interrogating In the future, one approach to cancer eQTL mapping will likely be to apply single-cell gene expression methods to 14 tumors-directly measuring gene expression in cancer and tumor-associated normal cells. For many cancer types 15 this should be possible, but currently, single-cell expression datasets are not on a scale required to map eQTL 16 profiles. For the foreseeable future, sample sizes available for gene expression in bulk tumors will remain orders-of-17 magnitude larger than single-cell datasets. Furthermore, single-cell methods bring additional biases, for example 18 isolating single cells can cause marked changes in expression and low starting amounts of RNA leads to high levels 19 of technical variability [30] . These studies have also encountered difficulty in isolating some cell types from Here, we have treated breast tumors as composed of two broad cell types, cancer and normal. Of course, these cell 26 types can be further subdivided. The normal component is composed of endothelial, epithelial, stromal and immune 27 cells, which can themselves be subdivided. Cancer cells are also heterogeneous-for example, the presence of stem-28 like cells. However, differentiating between the eQTL profiles of every cell type would require an interaction term 29 for each cell type. One would also need to be sufficiently confident that the cell type proportions were being 30 accurately estimated, which becomes more difficult given more similar expression profiles in less distinct subtypes.
31
Single-cell gene expression analyses of breast cancer have already shown that cancer and normal cells strongly 32 cluster in principal component analysis [18] , meaning breast cancer cells are transcriptionally much more similar to 33 each other than they are to tumor-associated normal cells. Thus, our approach provides a mechanism to identify 34 eQTLs that can be confidently attributed (wholly or in part) to cancer cells from tumor expression data. However, 35 future research in the development of statistical methods for analysis of tumor expression, or single cell-based 36 analyses, could benefit from further interrogating these complexities. Another assumption that our model makes, is that the presence/absence of normal cells does not itself affect 39 eQTLs in cancer cells, which could result in normal cells influencing tumor eQTL effect-sizes in a non-linear 40 fashion. While previous studies have shown that this linearity assumption is reasonable for expression data [19] , for genes where this is not true, it may be difficult or impossible to separate the eQTL profiles of tumor-resident cancer 42 and normal cells using any method, including single-cell RNA-seq. 43 
44
Additionally, our model, or any such model, cannot prove a non-association. It is incorrect to conclude that tumor 45 eQTLs that cannot be attributed to cancer cells are definitely not eQTLs in cancer cells, or are certainly eQTLs in 46 tumor-associated normal cells. The correct interpretation is that there is no statistical evidence for this eQTL in 47 cancer cells at the current sample size and given factors such as the accuracy with which the data were measured. 48 Notably, cancer eQTLs identified by the interaction model may still be eQTLs in other tumor-associated normal 49 cell types and these should not be interpreted as exclusively-cancer eQTLs.
50
Conclusion
51
We have elucidated a major shortcoming of current eQTL mapping strategies in cancer, in that eQTLs identified 52 from tumor expression data could arise from either cancer or tumor-associated normal cells. We have also proposed 53 a solution, which allows us to recover eQTL profiles for constituent cell types using expression data collected in a 54 mixture of cell types. We have applied this solution to breast cancer, where we showed that most eQTLs discovered 55 in tumors cannot be confidently attributed to cancer cells, once the possibility of these signals arising in tumor-56 associated normal cells is appropriately modeled. Overall, this work will improve the understanding of gene 57 regulation in cancer, including studying inherited cancer risk variants, disease development, and drug response. This 58 study also provides improved theoretical groundwork for deconvolution of eQTLs effects in other mixtures of cell 59 types, including normal human tissues.
Methods
61
Simulating bulk tumor expression data as a product of underlying "cancer" and "normal" expression data 62 63 We simulated cancer and normal gene expression datasets for 600 genes in 1000 samples-the approximate number 64 of patients in the TCGA breast cancer dataset. Cancer and normal expression datasets were then combined to 65 create a bulk tumor expression dataset, with each gene combined using a weighted mean based on purity estimates 66 for the sample. Combining expression datasets in this way assumes a linear relationship between expression levels in 67 the pure and mixed samples, which has previously been shown to be reasonable [19] . For all simulated SNPs, the 68 two alleles were simulated as occurring at an equal frequency (i.e. 500 homozygotes and 250 of each heterozygous 69 group, one of which was arbitrarily designated the minor allele). Simulated eQTL effect sizes (the fold-change in 70 gene expression with each copy of the minor allele) were drawn from a uniform distribution, which ranged from -.5 71 to .5, in steps of 0.01; this range was chosen as it covers the approximate range of the effect sizes observed in the 72 TCGA breast cancer data. Before adding eQTL effects, the expression level of each allele was randomly sampled 73 from a normal distribution of mean 1 and standard deviation 1 (TCGA expression data were also mapped to a 74 normal distribution of standard deviation 1 (see below)). The 600 simulated genes were split into 6 groups of 100, 75 each of which was treated differently, to represent the likely different types of scenarios that may arise in vivo: In 76 Group 1, eQTL effects were introduced in both cancer and normal expression datasets, but the effects were 77 randomly shuffled across genes, representing a scenario where there is an independent eQTL effect on each gene in 78 both cancer and normal tissue. In Group 2, eQTL effects were only introduced in the cancer expression data. In 79 Group 3 eQTL effects were only introduced in the normal expression data. In Group 4 eQTL effects were not 80 introduced in either. For genes in Group 5, the same eQTL effect was introduced in both expression datasets. In 81 Group 6, eQTL effects were simulated to be similar in cancer and normal tissues, by simulating identical eQTLs 82 then adding randomly generated noise in the normal expression data. Simulated purity estimates were derived from 1,000 randomly chosen consensus purity estimates [15] in real TCGA 85 breast cancer samples. When recovering the cancer eQTLs using the interaction model, noise was added to the 86 purity estimates, to simulate the fact that in real data these estimates will be imprecise: For each sample, noise was 87 added by randomly sampling a normal distribution with mean 0 and standard deviation 0.1; the resulting values were 88 then quantile normalized to the original purity estimates, thus preserving the distribution of the data precisely 89 ( Supplementary Figure 16 ). For Fig. 1(e) , the standard deviation of the noise generating normal distribution was 90 varied from 0.01 to 1.5 in steps of 0.025, thus simulating the effects of varying levels of error in the tumor purity 91 estimates; the resulting vector was quantile normalized to the original vector and the Pearson's correlation shown 92 on the x-axis of Fig. 1(e) were calculated between this noise-added vector and the original vector. All simulations 93 were performed in R and code to reproduce them is available in our supplementary materials. were also obtained from FireBrowse; gene level copy number was estimated as previously described [33] . PAM50 03 subtypes were obtained from the supplementary materials of Netanely et al. [34] . Gene expression and genotype data 04 were pre-processed and filtered primarily using the guidelines of GTEx: Expression data were quantile normalized.
05
The expression of each gene was then mapped to a standard normal distribution, with mean 0 and standard 06 deviation of 1. Genes not expressed in at least 75% of samples were removed. SNPs with a minor allele frequency 07 (MAF) of less than 5% were removed. Males, as well as Y chromosome SNPs and genes, were removed. We 08 estimated ancestry using the first 3 principal component of the genotype matrix. To account for expression 09 heterogeneity and unmeasured confounders, we also estimated 35 PEER factors [35] . The filtering steps yielded [EQ1] 16 Where y is the gene expression value; x is the genotype encoded as 0, 1 or 2; a is the 3 genotype principal 
Identifying cancer eQTLs using a linear model with an interaction term (the interaction model)
22
The model to identify cancer eQTLs is similar to the model described above but also includes tumor purity, 23 calculated by the CPE[15] method, as a covariate and a term for the interaction of tumor purity and genotype. The [EQ2]
29
The terms are as in EQ1, but with the addition of c, which represents the CPE estimate of tumor purity (0 < c < 1) 30 and c × x the interaction of tumor purity and genotype. Critically, tumor purity is encoded such that 0 represents 31 100% cancer cells and 1 represents 100% normal cells, meaning that the β1 term will have extrapolated an effect size 32 at 100% cancer cells. As above, the P-value for each eQTL was calculated by a t-test on the β1 term. A similar model proportion (term c in EQ2, but not bounded by 0 and 1); here, we use actual estimates of the cell type proportion, 37 bounded by 0 and 1-in this case the proportion of tumor-associated normal cells. The consequence of this is that 38 the main effect β1 now represents an extrapolated estimate of the eQTL effect size at 0% tumor-associated normal 39 cells, equivalent to 100% cancer cells. Thus, we recover cancer eQTLs by testing this main effect, rather than the 40 interaction term, which is actually a measure of how the magnitude of an eQTL differs between the two cell types 41 (as previously described in Westra et al.). Note 1: We also fit these models with gene copy number and methylation 42 status included as a covariate (for Supplementary Figure 3 and Supplementary Tables 4 & 5 ). Note 2: in EQ2 bold 43 typeface represents vectors and the 35 PEER factors were re-estimated accounting for the tumor purity covariate 44 not included in EQ1. 45 46 Comparing eQTL profiles between breast cancer cells (TCGA) and normal breast tissue (GTEx) 47 48 GTEx V6 summary data, including effect sizes and associated standard errors for each SNP-gene pair, were 49 obtained from the GTEx Portal. Cancer eQTL effects (β1 in EQ2) were compared for a given SNP-gene pair 50 between TCGA and GTEx using the effect size and associated standard error in each dataset. A Z-score for the 51 difference between these effects was calculated as follows[36,37]: The SE terms refer to the standard error estimates associated with the eQTL effect (βTCGA and βGTEx) in TCGA and 56 GTEx respectively. P-values were calculated from these Z-scores using the probability density function for a normal 57 distribution.
59
Gene set analysis of differential eQTLs between TCGA and GTEx using GOseq 60 61
Gene set analysis, which was used to identify differentially enriched biological processes between GTEx and TCGA 62 eQTLs, was performed using the GOseq[38] package in R. We considered a gene differentially regulated if it had at 63 least one associated eQTL that was significantly different (calculated using EQ3, FDR < 0.05) between TCGA 64 breast cancer and GTEx breast tissue. All genes expressed in both TCGA breast cancer and GTEx normal breast 65 tissue were used as the background list. The GOseq approach allowed us to use a six-knot monotonic spline 66 function to control for the increased probability of a gene appearing in the foreground list (i.e. differentially 67 regulated), given an increased number of associated SNPs. GOseq has previously been applied to control for similar We used the Michigan Imputation Sever v1.0.0[40] to impute genotypes for TCGA patients for the breast cancer 72 GWAS risk variants that were not directly genotyped on the Affymetrix SNP 6.0 array used by TCGA. We used the 73 Haplotype Reference Consortium (HRC version r1.1 2016)[41] reference panel. In addition to initial genotype 74 calling and quality control (QC) done by TCGA, we QC'ed germline genotypes further by removing SNPs with 75 MAF < 0.05, SNPs with missing genotype call rate >0.02, patients with missing call rate >0.02 and Hardy-Weinberg 76 Equilibrium (HWE) P < 1 × 10 -6 using Plink [42] . The input data were further validated and QC'ed by the server, The METABRIC data were obtained with permission from the European Genotype Archive. Raw Affymetrix 82 Genome-Wide Human SNP Array 6.0 CEL files were obtained from archive EGAD00010000164. We called 83 genotypes from these files using the Birdseed v2 algorithm under the default configuration implemented in 84 Affymetrix Genotyping Console. Notably, these data were measured from tumor tissue and are thus less reliable 85 than genotypes called from blood (as in TCGA); however, the METABRIC authors have previously used these 86 genotypes for eQTL mapping, and demonstrated that the results were reasonably consistent with those obtained 87 from genotypes generated from matched normal tissue [22] . We filtered SNPs with >.05 missing genotypes, MAF 88 <0.05 and only retained SNPs also included in the final TCGA analysis. The METABRIC "discovery" (n = 997) 89 normalized gene expression data were obtained from archive EGAD00010000210. We retained genes also included 90 in the TCGA analysis and mapped each gene to a normal distribution with mean 0 and standard deviation 1.
91
Covariates for expression heterogeneity and population structure were estimated and SNPs were mapped to genes 92 as in the TCGA analysis above. Note that the PEER algorithm did not converge on our METABRIC expression 93 dataset, thus we estimated expression heterogeneity using principal component analysis, applied to an expression 94 dataset where other model covariates (population structure, purity) had been regressed out. CPE tumor purity 95 estimates cannot be created in METABRIC as the required data types are not all available in this cohort; thus, we 96 approximated CPE tumor purity in METABRIC by fitting a lasso regression model to CPE tumor purity estimates 97 and gene expression in the TCGA cohort, then applied this model to METABRIC expression data; for consistency 98 we also mapped these estimates to the same quantiles of the TCGA CPE data. Similarly to TCGA, eQTLs were 99 then mapped using the "conventional" and "interaction" models in EQ1 & EQ2. the proportion of cancer cells is measured changes. The "Pearson correlation" on the x-axis is the correlation between 31 the known simulated proportions and those "measured" as more noise is added (see Methods). The dashed red line is 32 at 0.05, the rate at which the FDR was controlled for these tests using the Benjamini and Hochberg method. The 33
FDR is well controlled by the interaction model, even when the correlation between the real and measured (noise 34 added) proportions approaches 0.5. Note: if the cancer cell proportions are completely randomized, the true FDR is 35
22% (at the 5% threshold). Again, when calculating these true FDRs, the known simulated set of cancer eQTLs were 36 treated as the ground truth. represent 95% confidence intervals. The association from the conventional model applied to TCGA breast cancer 59 bulk tumors is shown in green (corresponding to Fig. 3(b) ). Shown in black are the effect sizes and confidence 60 intervals for the association of rs6458012 and MDGA1 when TCGA breast samples are divided into five equally 61 sized bins, based on each sample's estimated proportion of cancer cells. The estimated effect size decreases as the 62
proportion of cancer cells decreases. The extrapolated effect size in cancer cells, estimated by the interaction 63 model, is shown in red; this association is not statistically significant, illustrated by the 95% confidence interval 64
overlapping the grey dashed line, which represents an effect size of 0. This suggests the association recovered by 65 the conventional model did not arise in cancer cells. 66 d) A strip chart showing the association of rs6458012 and the expression MDGA1 in fibroblasts from GTEx. These 67 are associated (P = 6.3 × 10 -13 ) with the same directionality as identified in TCGA breast tumors ( Fig. 3(b) ). 68 e) A strip chart showing the association of rs6458012 and the expression MDGA1 in LCLs from GTEx. These are 69 associated (P = 1.4 × 10 -10 ) with the same directionality as identified in TCGA breast tumors ( Fig. 3(b) ). 70 71 Figure 4 : Classification and annotations for eQTLs identified using a conventional or an interaction model. to be derived from normal cells, based on Fig. 4(a) . axis. -log10 P-values from the interaction model for these same eQTLs are shown on the y-axis. Significance 89 thresholds of 0.05 are shown for the interaction model (green and purple dashed lines). 15 of these 24 eQTLs were no 90 longer significant (FDR > 0.05) when the possibility of these eQTLs arising from tumor-associated normal cells is 91 modeled.
92
(b) P-values and effect sizes for the nine eQTLs in Fig.5 (a) that were no longer even nominally significant (P > 0.05) 93 when the interaction model was used. For each eQTL, the effect size is represented by the red-blue divergent color 94 scale and the P-value by the size of the point; these are shown for TCGA bulk breast tumor (i.e. the conventional 95 model) and transformed fibroblast, breast tissue and LCLs from GTEx. All of these eQTLs are evident in at least one 96 of these GTEx tissues, with 100% concordant direction of effect as identified from TCGA breast bulk tumor 97 expression using the conventional model. Points are shown for associations with P < 0.05. The code to reproduce the results in this paper are on GitHub: https://github.com/paulgeeleher/cancerEqtls and 06 Open Science Framework: https://osf.io/z7uyp/ 07 Note that permission must be obtained from TCGA and METABRIC to obtain access to germline genotype 08 information. Competing interests 15 16 The authors declare that they have no competing interests. Author contributions 26 PG and RSH conceived the study. PG developed the statistical methods, performed the analysis and drafted the 27 paper. CS provided support/insight in statistical methods, deconvolution approaches and analysis. JF performed 28 exploratory initial analysis. AN and ANB provided analytical support. FW and ZZ performed genotype imputations.
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